Epidemiology of myelodysplastic syndromes.
Epidemiology of myelodysplastic syndromes.
复制标题
DOI：
10.1016/j.amjmed.2012.04.014
复制
发表时间：
2012-07
影响因子：
5.9
通讯作者：
Ma, Xiaomei
中科院分区：
文献类型：
--
作者：
Ma, Xiaomei
骨髓增生异常综合征（MDS）由一组异质性克隆造血干细胞恶性肿瘤组成，具有显着的发病率和高死亡率。 MDS 的发病率随着年龄的增长而显着增加，并且该疾病在白人和男性中最常见。据保守估计，美国每年新发 MDS 病例超过 10,000 例，目前居住在该国的 MDS 患者≥60,000 例。随着人口老龄化和人们对疾病认识的提高，记录在案的疾病负担预计在不久的将来将会升级。最近的研究发现了新的或不一致的病因，值得进一步研究。鉴于 MDS 患者的生存率较差，确定预后因素以更好地对患者进行风险分层以获得更有效的治疗非常重要。不同合并症与 MDS 预后的相关性以及各种合并症之间的潜在相互作用是一个有趣的研究领域。
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem cell malignancies with significant morbidity and high mortality. The incidence of MDS increases markedly with age, and the disease is most prevalent in individuals who are white and male. It is conservatively estimated that >10,000 new cases of MDS occur in the United States annually, and that ≥60,000 individuals with MDS currently reside in the country. With an aging population and an improving awareness of the disease, the documented disease burden is expected to escalate in the near future. Recent studies have identified new or inconsistent etiologic factors that warrant further research. Given the poor survival of individuals with MDS, it is important to identify prognostic factors to better risk-stratify patients for more effective treatment. The relevance of different comorbidities to MDS prognosis and the potential interaction between various comorbidities represents an interesting area of research.
登录
查看更多内容
影响因子：
6.2
作者：
Ma, Xiaomei;Does, Monique;Mayne, Susan T.
通讯作者：
Mayne, Susan T.
影响因子：
2.7
作者：
Wang R;Gross CP;Halene S;Ma X
通讯作者：
Ma X
影响因子：
5
作者：
Ma, Xiaomei;Lim, Unhee;Schatzkin, Arthur
通讯作者：
Schatzkin, Arthur
影响因子：
6.5
作者：
Rigolin, GM;Cuneo, A;Castoldi, G
通讯作者：
Castoldi, G
影响因子：
2.4
作者：
Sekeres, Mikkael A.
通讯作者：
Sekeres, Mikkael A.